Clasado clinches distribution deal for French market
06 Apr 2022 --- Clasado Biosciences is expanding its presence across the EU following a new distribution agreement with French ingredient specialist Nutragroup. The move will see its Bimuno prebiotic galactooligosaccharide (GOS) ingredient available to health and well-being formulators in France.
“Europe is one of the largest markets for prebiotics, and the category is set to grow at a very robust 7.11% CAGR to 2025 in Europe, so it’s clear to see that demand is still surging,” says Per Rehné, CEO of Clasado.
“Nutragroup is a highly established leader in the health and nutrition market, with a strong presence. We look forward to seeing Bimuno make its mark in the region.”
Establishing its ingredient in the global market, Clasado has increased its geographic reach with expansion into regions such as North America, Asia and EMEA. In October, Clasado partnered with specialty healthcare ingredient distributor Pathway International, making Bimuno available across Australia and New Zealand.
Europe is one of the largest markets for prebiotics.“Demand is king”
The ingredient is available in powder or syrup form, aiming to be versatile. Bimuno is highly stable under a wide range of heat and acidities, making it suitable for a broad range of applications, such as standalone supplements, including powders and gummies, as well as functional food applications.
The ingredient nourishes bifidobacteria, a beneficial bacterium in the gut that is understood to impact key areas of health, including digestive health, mental health, cognition and immune function.
“In today’s market, consumer demand is king. With better gut health high on the agenda, we’re proud to add Bimuno to our ingredient range,” Kevin Wilson, business development director at Nutragroup, underscores.
Bimuno aims to be simple for formulators to use, with a low effective dose and stability that means it can be added to formulations at any point in the manufacturing process, he adds.
“France, like the wider European market, is acknowledging the potential of prebiotics – the time for formulators and nutrition brands to embrace the benefits is now. With Bimuno, the path forward is clear for businesses looking to connect with an engaged and proactive health audience.”
Commercializing science
With gut health continuing to drive the consumer health agenda, Bimuno is designed to make complex microbiome science simple and easy to understand, the company underscores.Bimuno is supported by over 100 scientific publications, including more than 20 clinical trials, the company notes.
Describing the item as the “most studied prebiotic of its kind,” Rehné notes: “We are continuing to transition from an exclusively science-focused business to one that makes the science commercially available and accessible.”
Prebiotics are continuing to gain ground across markets, with consumer education and scientific research fueling the rise in demand for gut-healthy formulations.
By Andria Kades
